https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209939s015,209940s015,219104s001lbl.pdf
Letermovir is a substrate of organic anion-transporting polypeptide 1B1/3 (OATP1B1/3) and P-glycoprotein (P-gp) transporters and UDP-glucuronosyltransferase 1A1/3 (UGT1A1/3) enzyme
https://www.prevymis.com/
Find out more information about PREVYMIS® (letermovir). Learn about PREVYMIS for appropriate HSCT and kidney transplant patients and talk to your doctor about PREVYMIS.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b49df80-be4f-47e0-a0b7-123f3e69395b
Jan 14, 2026 · NDC 0006-3075-02 - PREVYMIS® (letermovir) tablets - 240 mg per tablet - Rx only - 28 Tablets - This carton contains a total of 28 tablets - packaged within 4 dose
https://www.ema.europa.eu/en/documents/product-information/prevymis-epar-product-information_en.pdf
Eligible subjects who completed letermovir prophylaxis through ~100 days post-HSCT were randomised (2:1) to receive letermovir or placebo from Week 14 through Week 28 post-HSCT.
https://fda.report/DailyMed/1b49df80-be4f-47e0-a0b7-123f3e69395b
PREVYMIS injection must be administered through a sterile 0.2 micron or 0.22 micron polyethersulfone (PES) in-line filter. Administer by intravenous infusion via a peripheral cathe
https://medlibrary.org/lib/rx/meds/prevymis/
Jan 14, 2026 · PREVYMIS ® is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at le
https://cpb-us-w2.wpmucdn.com/u.osu.edu/dist/1/104737/files/2022/04/Letermovir-Drug-Monograph.pdf
Letermovir is commercially available as a preservative-free, sterile concentrate for injection that must be diluted prior to IV infusion.The concentrate should appear clear and col
https://www.merck.com/product/usa/pi_circulars/p/prevymis/prevymis_pi.pdf
PREVYMIS® is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least 6 kg who are
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219104s000lbl.pdf
Letermovir is a substrate of organic anion-transporting polypeptide 1B1/3 (OATP1B1/3) and P-glycoprotein (P-gp) transporters and UDP-glucuronosyltransferase 1A1/3 (UGT1A1/3) enzyme
https://medicarcp.com/website/pdf/spc/10303%20-%20en.pdf
PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transpla